Although second-generation agents are effective in patients with non-small cell lung cancer (NSCLC) with EGFR mutations, they are associated with relatively low progression-free survival (approximately 10 months) and side effects such as rash and diarrhea. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.